HK1253040A1 - 新型jak1选择性抑制剂及其用途 - Google Patents
新型jak1选择性抑制剂及其用途 Download PDFInfo
- Publication number
- HK1253040A1 HK1253040A1 HK18112420.5A HK18112420A HK1253040A1 HK 1253040 A1 HK1253040 A1 HK 1253040A1 HK 18112420 A HK18112420 A HK 18112420A HK 1253040 A1 HK1253040 A1 HK 1253040A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compound
- nrr
- group
- disease
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| US62/403,660 | 2016-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1253040A1 true HK1253040A1 (zh) | 2019-06-06 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18112420.5A HK1253040A1 (zh) | 2016-10-03 | 2017-09-30 | 新型jak1选择性抑制剂及其用途 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | USRE49834E1 (enExample) |
| EP (1) | EP3509591B1 (enExample) |
| JP (1) | JP7089141B2 (enExample) |
| KR (1) | KR102399848B1 (enExample) |
| CN (2) | CN113214278B (enExample) |
| AU (3) | AU2017339417C1 (enExample) |
| CA (1) | CA3039178A1 (enExample) |
| DK (1) | DK3509591T3 (enExample) |
| EA (1) | EA201990523A1 (enExample) |
| ES (1) | ES2901216T3 (enExample) |
| HK (1) | HK1253040A1 (enExample) |
| HR (1) | HRP20211965T1 (enExample) |
| HU (1) | HUE058120T2 (enExample) |
| IL (3) | IL265358B (enExample) |
| MX (1) | MX390005B (enExample) |
| NZ (1) | NZ751284A (enExample) |
| PL (1) | PL3509591T3 (enExample) |
| PT (1) | PT3509591T (enExample) |
| RS (1) | RS62695B1 (enExample) |
| WO (1) | WO2018067422A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX390005B (es) | 2016-10-03 | 2025-03-20 | Hangzhou Highlightll Pharmaceutical Co Ltd | Inhibidores selectivos de jak1 novedosos y usos de los mismos. |
| SI3568396T1 (sl) | 2017-01-11 | 2021-04-30 | Leo Pharma A/S | Novi derivati amino-imidazopiridina koz zaviralci Janus kinaze in njihova farmacevtska uporaba |
| EA202191170A1 (ru) | 2018-10-31 | 2021-07-27 | Инсайт Корпорейшн | Комбинированная терапия для лечения гематологических заболеваний |
| MA55201A (fr) * | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| TW202102222A (zh) * | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
| CA3142629A1 (en) * | 2019-06-06 | 2020-12-10 | Highlightll Pharmaceutical (Hainan) Co., Ltd | Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt |
| JP7320628B2 (ja) | 2019-06-06 | 2023-08-03 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | フロイミダゾピリジン化合物の合成方法、フロイミダゾピリジン化合物の結晶形態およびそれらの塩の結晶形態 |
| EP4153566A1 (en) | 2020-05-19 | 2023-03-29 | Bayer CropScience Aktiengesellschaft | Azabicyclic(thio)amides as fungicidal compounds |
| JP7729845B2 (ja) | 2020-06-10 | 2025-08-26 | バイエル、アクチエンゲゼルシャフト | 新規殺菌剤としてのアザビシクリル置換複素環 |
| EP4351584A4 (en) * | 2021-06-07 | 2025-04-23 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE |
| IL313097A (en) * | 2021-09-13 | 2024-07-01 | Hangzhou Highlightll Pharmaceutical Co Ltd | Methods of treating cns disorders |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| KR100501022B1 (ko) | 1998-07-28 | 2005-07-18 | 다나베 세이야꾸 가부시키가이샤 | 장내 적소 방출형 제제 |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| WO2005085227A1 (en) | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| CN101277965A (zh) * | 2005-08-04 | 2008-10-01 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
| CA2775942A1 (en) * | 2009-09-29 | 2011-04-07 | Xcovery Holding Company Llc | Pi3k (delta) selective inhibitors |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| MX2013003913A (es) | 2010-10-08 | 2013-09-26 | Abbvie Inc | Compuestos de furo [3, 2-d] pirimidina. |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| CR20160553A (es) | 2014-04-30 | 2017-04-25 | Incyte Corp | Procesos para preparar un inhibidor de jak1 y nuevas formas de este |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| MX390005B (es) | 2016-10-03 | 2025-03-20 | Hangzhou Highlightll Pharmaceutical Co Ltd | Inhibidores selectivos de jak1 novedosos y usos de los mismos. |
-
2017
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 CA CA3039178A patent/CA3039178A1/en active Pending
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108366994B (zh) | 新型Jak1选择性抑制剂及其用途 | |
| EP3555096B1 (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases | |
| RU2732405C2 (ru) | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ | |
| TWI406864B (zh) | 化合物 | |
| EP3939979A1 (en) | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine | |
| US12297194B2 (en) | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | |
| EP2571884A2 (en) | Mtor selective kinase inhibitors | |
| WO2018130563A1 (en) | Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof | |
| WO2019070167A1 (ru) | Ингибиторы рецептора эпидермального фактора роста | |
| WO2019057112A1 (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| CN113214230B (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| HK40047523B (en) | Novel jak1 selective inhibitors and uses thereof | |
| HK40047523A (en) | Novel jak1 selective inhibitors and uses thereof | |
| WO2020007698A1 (en) | Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof | |
| HK40004735B (en) | Novel jak1 selective inhibitors and uses thereof | |
| EA040948B1 (ru) | Селективные ингибиторы jak1 и их применение | |
| BR112019005969B1 (pt) | Inibidores seletivos de jak1 e usos dos mesmos | |
| HK40079587B (zh) | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 | |
| WO2025169375A1 (ja) | ４員環構造で置換された３級アミド誘導体 |